• ABOUT
  • TEAM
    • Executive Team
    • Tumor Board
    • Scientific Advisory Board
    • Experts
  • PORTFOLIO
    • IMGATUZUMAB
    • ISTIRATUMAB
  • ONGOING
  • SCIENTIFIC CONTENTS
    • Istiratumab
    • Ewing sarcoma
    • Rhadbomyosarcoma
    • Nasopharyngeal cancer
    • Industry
PEGASCY PEGASCY PEGASCY
  • ABOUT
  • TEAM
    • Executive Team
    • Tumor Board
    • Scientific Advisory Board
    • Experts
  • PORTFOLIO
    • IMGATUZUMAB
    • ISTIRATUMAB
  • ONGOING
  • SCIENTIFIC CONTENTS
    • Istiratumab
    • Ewing sarcoma
    • Rhadbomyosarcoma
    • Nasopharyngeal cancer
    • Industry

Rhabdomyosarcoma


HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy.


Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.


Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.


 

Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma


Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse.


Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study.


A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.


Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft model

© PEGASCY 2023, Créé parCédric Verjat, CED-WEB | Website & Privacy Policies